HomeNewsBusinessStocksWockhardt plunges 5% on USFDA’s hygiene concerns

Wockhardt plunges 5% on USFDA‘s hygiene concerns

An inspection by the US Food and Drug Administration at Wockhardt's Chikalthana plant reveals that it had unhygienic toilets, soiled uniforms and mold growing in storage areas. The plant produces Toprol XL, a heart tablet.

September 27, 2013 / 15:00 IST
Story continues below Advertisement

Wockhardt is locked in lower circuit of five percent at Rs 551 on the NSE after reports that United States Food and Drug Administration’s (FDA) inspection at the company’s Chikalthana plant found urine spilling over open drains. 

Also read: USFDA to Agila: Use of non-sterile gloves a grave violation
The US regulator’s assessment came up with 16 observations. It revealed that the plant had unhygienic toilets. Mold was growing in the storage areas of the factory. It also found soiled uniforms around the area.
The factory produces heart tablets called Toprol XL. Wockhardt currently holds 26 percent of Toprol XL market share in the US.
first published: Sep 27, 2013 03:00 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!